(February 22, 2017, 12:56 PM EST) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals erred in finding that the supply of one component of a five-component genetic testing kit manufactured abroad triggers domestic patent liability under the Patent Act, 35 U.S.C. §271(f)(1), the U.S. Supreme Court ruled Feb. 22 (Life Technologies Corp. v. Promega Corp., No. 14-1538, U.S. Sup.)....